Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy
In Vivo · 2026
DOI: 10.21873/invivo.14437 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, 2026. Verfasst von Masaaki Yanishi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Andrology, Kansai Medical University, Osaka, Japan masaaki.yanishi@gmail.com. Hauptthemen laut MEDLINE: Nephroureterectomy, Nivolumab, Carcinoma, Transitional Cell, Urologic Neoplasms. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology and Andrology, Kansai Medical University, Osaka, Japan masaaki.yanishi@gmail.com.
- Department of Urology and Andrology, Kansai Medical University, Osaka, Japan.
Zitieren
APA
Yanishi, M., Matsushita, J., Kita, A., Mishima, T., & Kinoshita, H. (2026). Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. In Vivo. https://doi.org/10.21873/invivo.14437
Vancouver
Yanishi M, Matsushita J, Kita A, Mishima T, Kinoshita H. Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy. In Vivo. 2026. doi:10.21873/invivo.14437
BibTeX
@article{Yanishi2026,
author = {Yanishi, Masaaki and Matsushita, Jun and Kita, Akiyo and Mishima, Takao and Kinoshita, Hidefumi},
title = {Real-world Feasibility of Adjuvant Nivolumab for High-risk Upper Tract Urothelial Carcinoma After Radical Nephroureterectomy},
journal = {In Vivo},
year = {2026},
doi = {10.21873/invivo.14437}
}
EUVIMED